14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $11.21 $15.20 Wednesday, 1st May 2024 PLRX stock ended at $12.66. This is 7.11% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 9.80% from a day low at $11.73 to a day high of $12.88.
90 days $11.21 $18.45
52 weeks $11.21 $24.74

Historical Pliant Therapeutics Inc. prices

Date Open High Low Close Volume
May 01, 2024 $11.82 $12.88 $11.73 $12.66 678 639
Apr 30, 2024 $11.86 $12.15 $11.78 $11.82 478 916
Apr 29, 2024 $11.99 $12.48 $11.73 $12.09 238 975
Apr 26, 2024 $11.90 $12.06 $11.74 $11.81 359 681
Apr 25, 2024 $11.68 $11.90 $11.21 $11.88 588 174
Apr 24, 2024 $12.55 $12.55 $11.73 $11.90 368 605
Apr 23, 2024 $12.58 $12.88 $12.49 $12.52 236 712
Apr 22, 2024 $12.55 $12.80 $12.37 $12.60 198 639
Apr 19, 2024 $12.14 $12.55 $12.00 $12.52 285 756
Apr 18, 2024 $12.81 $12.87 $12.01 $12.19 342 731
Apr 17, 2024 $13.29 $13.29 $12.84 $12.86 266 955
Apr 16, 2024 $13.40 $13.66 $13.22 $13.26 427 138
Apr 15, 2024 $14.15 $14.15 $13.47 $13.55 259 874
Apr 12, 2024 $14.33 $14.57 $14.00 $14.15 214 720
Apr 11, 2024 $14.28 $14.71 $14.09 $14.47 244 542
Apr 10, 2024 $14.34 $14.39 $13.93 $14.15 327 900
Apr 09, 2024 $14.73 $15.18 $14.73 $14.92 179 098
Apr 08, 2024 $14.69 $14.83 $14.52 $14.72 161 133
Apr 05, 2024 $14.50 $14.98 $14.27 $14.65 253 817
Apr 04, 2024 $14.70 $15.20 $14.42 $14.55 390 228
Apr 03, 2024 $14.52 $14.62 $14.27 $14.43 470 379
Apr 02, 2024 $14.51 $14.68 $14.30 $14.68 275 552
Apr 01, 2024 $14.97 $14.97 $14.30 $14.81 269 435
Mar 28, 2024 $14.69 $14.96 $14.38 $14.90 274 314
Mar 27, 2024 $14.33 $14.88 $14.10 $14.55 243 600
Click to get the best stock tips daily for free!

About Pliant Therapeutics Inc.

Pliant Therapeutics. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which complet... PLRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT